100 related articles for article (PubMed ID: 29360358)
1. Design, Synthesis, and Preclinical Evaluation of Fused Pyrimidine-Based Hydroxamates for the Treatment of Hepatocellular Carcinoma.
Chen D; Soh CK; Goh WH; Wang H
J Med Chem; 2018 Feb; 61(4):1552-1575. PubMed ID: 29360358
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis and biological evaluation of novel hybrids targeting mTOR and HDACs for potential treatment of hepatocellular carcinoma.
Zhai S; Zhang H; Chen R; Wu J; Ai D; Tao S; Cai Y; Zhang JQ; Wang L
Eur J Med Chem; 2021 Dec; 225():113824. PubMed ID: 34509167
[TBL] [Abstract][Full Text] [Related]
3. Arenobufagin, a natural bufadienolide from toad venom, induces apoptosis and autophagy in human hepatocellular carcinoma cells through inhibition of PI3K/Akt/mTOR pathway.
Zhang DM; Liu JS; Deng LJ; Chen MF; Yiu A; Cao HH; Tian HY; Fung KP; Kurihara H; Pan JX; Ye WC
Carcinogenesis; 2013 Jun; 34(6):1331-42. PubMed ID: 23393227
[TBL] [Abstract][Full Text] [Related]
4. Des-gamma-carboxy prothrombin antagonizes the effects of Sorafenib on human hepatocellular carcinoma through activation of the Raf/MEK/ERK and PI3K/Akt/mTOR signaling pathways.
Cui SX; Shi WN; Song ZY; Wang SQ; Yu XF; Gao ZH; Qu XJ
Oncotarget; 2016 Jun; 7(24):36767-36782. PubMed ID: 27167344
[TBL] [Abstract][Full Text] [Related]
5. PKI-587 and sorafenib targeting PI3K/AKT/mTOR and Ras/Raf/MAPK pathways synergistically inhibit HCC cell proliferation.
Gedaly R; Angulo P; Hundley J; Daily MF; Chen C; Evers BM
J Surg Res; 2012 Aug; 176(2):542-8. PubMed ID: 22261591
[TBL] [Abstract][Full Text] [Related]
6. Combination of cetuximab and rapamycin enhances the therapeutic efficacy in hepatocellular carcinoma.
Geng J; Li X; Lang X; Qiao C; Hu M; Yang J; Feng J; Lv M
Technol Cancer Res Treat; 2014 Aug; 13(4):377-85. PubMed ID: 24325131
[TBL] [Abstract][Full Text] [Related]
7. Dual targeting of mTORC1/C2 complexes enhances histone deacetylase inhibitor-mediated anti-tumor efficacy in primary HCC cancer in vitro and in vivo.
Shao H; Gao C; Tang H; Zhang H; Roberts LR; Hylander BL; Repasky EA; Ma WW; Qiu J; Adjei AA; Dy GK; Yu C
J Hepatol; 2012 Jan; 56(1):176-83. PubMed ID: 21835141
[TBL] [Abstract][Full Text] [Related]
8. The role of PI3K/mTOR inhibition in combination with sorafenib in hepatocellular carcinoma treatment.
Gedaly R; Angulo P; Chen C; Creasy KT; Spear BT; Hundley J; Daily MF; Shah M; Evers BM
Anticancer Res; 2012 Jul; 32(7):2531-6. PubMed ID: 22753710
[TBL] [Abstract][Full Text] [Related]
9. Autophagy potentiates the anti-cancer effects of the histone deacetylase inhibitors in hepatocellular carcinoma.
Liu YL; Yang PM; Shun CT; Wu MS; Weng JR; Chen CC
Autophagy; 2010 Nov; 6(8):1057-65. PubMed ID: 20962572
[TBL] [Abstract][Full Text] [Related]
10. [Research advances in the mammalian target of rapamycin signaling pathway and its inhibitors in treatment of hepatocellular carcinoma].
Li SZ; Xu F; Sun CQ; Xu P
Zhonghua Gan Zang Bing Za Zhi; 2018 Jan; 26(1):77-80. PubMed ID: 29804369
[TBL] [Abstract][Full Text] [Related]
11. Discovery of benzenesulfonamide derivatives as potent PI3K/mTOR dual inhibitors with in vivo efficacies against hepatocellular carcinoma.
Chen Y; Zhang L; Yang C; Han J; Wang C; Zheng C; Zhou Y; Lv J; Song Y; Zhu J
Bioorg Med Chem; 2016 Mar; 24(5):957-66. PubMed ID: 26819001
[TBL] [Abstract][Full Text] [Related]
12. Capsaicin and sorafenib combination treatment exerts synergistic anti‑hepatocellular carcinoma activity by suppressing EGFR and PI3K/Akt/mTOR signaling.
Dai N; Ye R; He Q; Guo P; Chen H; Zhang Q
Oncol Rep; 2018 Dec; 40(6):3235-3248. PubMed ID: 30272354
[TBL] [Abstract][Full Text] [Related]
13. Comprehensive anti-tumor effect of Brusatol through inhibition of cell viability and promotion of apoptosis caused by autophagy via the PI3K/Akt/mTOR pathway in hepatocellular carcinoma.
Ye R; Dai N; He Q; Guo P; Xiang Y; Zhang Q; Hong Z; Zhang Q
Biomed Pharmacother; 2018 Sep; 105():962-973. PubMed ID: 30021391
[TBL] [Abstract][Full Text] [Related]
14. Hydrogen sulfide promotes autophagy of hepatocellular carcinoma cells through the PI3K/Akt/mTOR signaling pathway.
Wang SS; Chen YH; Chen N; Wang LJ; Chen DX; Weng HL; Dooley S; Ding HG
Cell Death Dis; 2017 Mar; 8(3):e2688. PubMed ID: 28333142
[TBL] [Abstract][Full Text] [Related]
15. Ruscogenin suppressed the hepatocellular carcinoma metastasis via PI3K/Akt/mTOR signaling pathway.
Hua H; Zhu Y; Song YH
Biomed Pharmacother; 2018 May; 101():115-122. PubMed ID: 29477471
[TBL] [Abstract][Full Text] [Related]
16. Oral administration of indole substituted dipyrido[2,3-d]pyrimidine derivative exhibits anti-tumor activity via inhibiting AKT and ERK1/2 on hepatocellular carcinoma.
Gao X; Cen L; Li F; Wen R; Yan H; Yao H; Zhu S
Biochem Biophys Res Commun; 2018 Nov; 505(3):761-767. PubMed ID: 30293685
[TBL] [Abstract][Full Text] [Related]
17. Sustained antitumor activity by co-targeting mTOR and the microtubule with temsirolimus/vinblastine combination in hepatocellular carcinoma.
Zhou Q; Lui VW; Lau CP; Cheng SH; Ng MH; Cai Y; Chan SL; Yeo W
Biochem Pharmacol; 2012 May; 83(9):1146-58. PubMed ID: 22285225
[TBL] [Abstract][Full Text] [Related]
18. Alpha1-ACT Functions as a Tumour Suppressor in Hepatocellular Carcinoma by Inhibiting the PI3K/AKT/mTOR Signalling Pathway via Activation of PTEN.
Zhu H; Liu Q; Tang J; Xie Y; Xu X; Huang R; Zhang Y; Jin K; Sun B
Cell Physiol Biochem; 2017; 41(6):2289-2306. PubMed ID: 28456796
[TBL] [Abstract][Full Text] [Related]
19. Columbamine suppresses hepatocellular carcinoma cells through down-regulation of PI3K/AKT, p38 and ERK1/2 MAPK signaling pathways.
Lin Z; Li S; Guo P; Wang L; Zheng L; Yan Z; Chen X; Cheng Z; Yan H; Zheng C; Zhao C
Life Sci; 2019 Feb; 218():197-204. PubMed ID: 30582951
[TBL] [Abstract][Full Text] [Related]
20. PI3K/AKT/mTOR-dependent stabilization of oncogenic far-upstream element binding proteins in hepatocellular carcinoma cells.
Samarin J; Laketa V; Malz M; Roessler S; Stein I; Horwitz E; Singer S; Dimou E; Cigliano A; Bissinger M; Falk CS; Chen X; Dooley S; Pikarsky E; Calvisi DF; Schultz C; Schirmacher P; Breuhahn K
Hepatology; 2016 Mar; 63(3):813-26. PubMed ID: 26901106
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
